Kroger stock falls after Amazon announces major grocery expansion
Neena M. Patil, the Executive Vice President and Chief Legal Officer of Jazz Pharmaceuticals plc (NASDAQ:JAZZ), recently executed a notable transaction involving the sale of company shares. According to the SEC filing, Patil sold 3,800 ordinary shares on February 27, 2025, at a weighted average price of $144.87 per share, totaling $550,506. The transaction occurs as Jazz, currently valued at $8.5 billion, trades near its 52-week high of $148.06, with InvestingPro analysis suggesting the stock remains undervalued.
Following this transaction, Patil holds 33,318 shares directly. Additionally, she acquired restricted stock units, which are set to vest in the future. This acquisition included 12,518 units, which will vest in equal annual installments over four years starting March 5, 2025, and 5,778 units that will vest fully by June 30, 2026. These transactions were part of the company’s 2011 Equity Incentive Plan. The company maintains impressive gross profit margins of 92.4%, and InvestingPro data reveals 13 additional key insights about Jazz’s financial health and market position. For comprehensive insider trading analysis and detailed financial metrics, access the full Pro Research Report available on InvestingPro.
In other recent news, Jazz Pharmaceuticals reported its Q4 2024 earnings, surpassing analyst expectations with an earnings per share (EPS) of $6.60 compared to the forecasted $5.79. The company’s revenue for the quarter reached $1.1 billion, exceeding the anticipated $1.06 billion. Jazz Pharmaceuticals also provided financial guidance for 2025, with expected revenue between $4.15 billion and $4.4 billion, indicating a 5% growth. Needham analyst Ami Fadia raised the price target for Jazz Pharmaceuticals to $210, maintaining a Buy rating, following the company’s earnings release and positive updates, including a settlement extending Epidiolex’s market exclusivity into the late 2030s. RBC Capital Markets adjusted its price target for Jazz Pharmaceuticals to $178, while maintaining an Outperform rating, citing the company’s fiscal year 2025 revenue outlook aligning with market expectations. Despite a quieter pipeline, Jazz Pharmaceuticals’ commercial success and strategic management of its portfolio continue to be viewed positively. The company also announced the delay of topline results from the Phase III HERIZONGEA-01 study for Ziihera to the second half of the year.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.